Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors

NCT02713529 is registered in ClinicalTrials.gov with AmMax Bio, Inc. as lead sponsor.

NCT NCT02713529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02713529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
Lead sponsor
AmMax Bio, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
April 14, 2016
Completion date
May 17, 2019
Enrollment
117 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small cell lung cancer, pancreatic cancer